Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases

Published:2020-11-23 Issue:9 Volume:148 Page:2203-2211
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

George Gincy¹^ORCID,Garmo Hans¹,Scailteux Lucie‐Marie²³,Balusson Frédéric²,De Coster Greet⁴,De Schutter Harlinde⁴,Kuiper Josephina G.⁵,Oger Emmanuel³,Verbeeck Julie⁴,Van Hemelrijck Mieke¹^ORCID

Affiliation:

1. King's College London, Translational Oncology and Urology Research London UK

2. University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research Rennes France

3. Rennes Hospital University, Pharmacovigilance Pharmacoepidemiology and Drug Information Center Rennes France

4. Belgian Cancer Registry Brussels Belgium

5. PHARMO Institute for Drug Outcomes Research Utrecht The Netherlands

Funder

Ferring

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33397

Reference43 articles.

1. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

2. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

3. Testosterone and Atherosclerosis in Aging Men

4. Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

5. Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer;Urologic Oncology: Seminars and Original Investigations;2024-07

2. A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk;Clinical Pharmacology in Drug Development;2024-05-17

3. Androgen Deprivation Therapy/Androgen Receptor Signaling Inhibitor Treatments for Prostate Cancer: Pathophysiology and Review of Effects on Cardiovascular Disease;Southern Medical Journal;2024-05

4. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer;JAMA Oncology;2024-05-01

5. Cardiovascular risk in ADT recipients: does the type of ADT matter?;Prostate Cancer and Prostatic Diseases;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3